OncologyEducation

Evidence-based, educational resources for the oncology community. Authored exclusively by a leading international faculty of oncology.

[OncologyEducation @OncEd]

🚨 Final day at #ASCO2026!

This week we've seen advances in AI, blood-based biomarkers, immunotherapy, and precision oncology—all focused on delivering the right treatment to the right patient at the right time.

Stay tuned for Day 4 highlights. 👇

[OncologyEducation @OncEd]

🧬 @DrBetofMDPhD shares phase II results of OBX115, an engineered TIL therapy showing a 67% response rate in advanced melanoma, with a favorable safety profile and no need for systemic IL-2.

https://t.co/ChjGqcvrE9

#ASCO2026 #Melanoma

[OncologyEducation @OncEd]

🧬 Dr. Paolo Ciracì presents an AI-powered histopathology biomarker that may help personalize upfront treatment decisions in metastatic colorectal cancer.

https://t.co/JM4d03gHvk

[OncologyEducation @OncEd]

🎗️ Dr. Ghassan Abou-Alfa shares results from EMERALD-3, where adding STRIDE + TACE improved PFS to ~13 months versus 8–9 months with TACE alone in intermediate-stage HCC, supporting a potential new standard of care.

https://t.co/7eRhHn15u8

#ASCO2026

[OncologyEducation @OncEd]

🧬 Dr. Elizabeth McDonald discusses research linking GLP-1 agonist use to a 30% lower incidence of breast cancer, highlighting a potential new avenue for cancer prevention.

https://t.co/EiAY04MYPA

#ASCO2026

[OncologyEducation @OncEd]

🫁 Dr. Jamie Chaft reviews the EA5142 study, where adjuvant nivolumab showed no meaningful DFS benefit after surgery and chemotherapy, reinforcing the role of pre-operative chemoimmunotherapy in NSCLC.

https://t.co/dxODVPRjOo

#ASCO2026

[OncologyEducation @OncEd]

👁️ Dr. Marlana Orloff shares OptimUM-02 findings showing darovasertib plus crizotinib improved outcomes in metastatic uveal melanoma, addressing a major unmet need for HLA-A2 negative patients.

https://t.co/rvTjRJ2IbF

#ASCO2026 #Melanoma

[OncologyEducation @OncEd]

🎗️ Dr. Shilpa Gupta discusses the phase III MAIN-CAV trial, where adding cabozantinib to avelumab maintenance showed no clear benefit in advanced urothelial cancer, while biomarker analyses continue.

https://t.co/w1FWzCgnqq

#ASCO2026

[OncologyEducation @OncEd]

📊 Dr. Claudio Vernieri presents PALMARES-2 data showing selected patients with HR+/HER2�� advanced breast cancer may benefit from continuing first-line ET + CDK4/6 inhibition beyond progression.

https://t.co/9vcpQjvOjW

#ASCO2026

[OncologyEducation @OncEd]

🎗️ Dr. Lucy Gilbert shares subgroup analyses from the phase III ROSELLA trial, showing relacorilant maintained its survival benefit regardless of prior taxane exposure in platinum-resistant ovarian cancer.

https://t.co/sAEtweuAKR

#ASCO2026

[OncologyEducation @OncEd]

🤖 Dr. Paolo Ciracì highlights an AI-powered histopathology biomarker that may help identify which patients with metastatic colorectal cancer benefit most from upfront treatment intensification.

https://t.co/JM4d03gHvk

#ASCO2026

[OncologyEducation @OncEd]

🔬 Dr. Maggie Banys-Paluchowski presents AXSANA findings showing tumour biology—not the number of involved lymph nodes—is the strongest predictor of axillary response after neoadjuvant therapy.

https://t.co/7Q7t92Wedm

#ASCO2026

[OncologyEducation @OncEd]

📈 Dr. Robert Stein discusses the OPTIMA trial, demonstrating that genomic testing can identify many patients with ER+/HER2− early breast cancer who may safely avoid chemotherapy.

https://t.co/QIGl0NPbxP

#ASCO2026

[OncologyEducation @OncEd]

🧬 Dr. Pavlos Msaouel presents findings supporting EGFR blockade in SMARCB1-deficient renal medullary carcinoma, offering a potential new treatment strategy for this rare disease.

https://t.co/OOpqlqMQYA

#ASCO2026

[OncologyEducation @OncEd]

🥗 Dr. Livia Augustin explores how Mediterranean diet, physical activity, and vitamin D may influence breast cancer recurrence and cardiometabolic health in a multicentre randomized study.

https://t.co/Fk5FoTpXTm

#ASCO2026

[OncologyEducation @OncEd]

🤝 Dr. Achim Wöckel reviews the BETTER-CARE trial, evaluating individualized, needs-based follow-up care for patients after primary breast cancer treatment.

https://t.co/1M8huTWMRi

#ASCO2026

[OncologyEducation @OncEd]

🧬 @DrBetofMDPhD discusses phase II results of OBX-115, an engineered TIL therapy featuring membrane-bound IL-15, showing promising activity in advanced melanoma after immune checkpoint inhibitors.

https://t.co/ChjGqcvrE9

#ASCO2026

[OncologyEducation @OncEd]

🎗️ @ATarhiniMDPhD reviews a phase II study of neoadjuvant ipilimumab, nivolumab, and relatlimab in high-risk resectable melanoma, highlighting the continued evolution of combination immunotherapy approaches.

https://t.co/wZkfheSijH

#ASCO2026

[OncologyEducation @OncEd]

🧪 @ArndtVogel presents findings from IMbrave251, evaluating atezolizumab-based strategies in advanced hepatocellular carcinoma following prior atezolizumab and bevacizumab treatment.

https://t.co/RHeuQJtJyt

#ASCO2026

[OncologyEducation @OncEd]

📍 Day 3 at #ASCO2026

Another day of groundbreaking science, expert perspectives, and data that could shape the future of cancer care.

Follow along as we share key highlights and presenter insights direct from Chicago.

#ASCO #Oncology